J&J's Blood Cancer Combo Cuts Death Risk by 89% in Late-Stage Trial
JNJ sits 57% above its 52-week low of $164.23 on light trading volume (0.1× avg).
Summary
J&J's combination of Tecvayli and Talvey reduced the risk of disease progression or death by 89% in a late-stage trial for relapsed/refractory multiple myeloma. The results showed statistically significant improvements in both progression-free and overall survival. This builds on recent positive data for Talvey and Darzalex Faspro in earlier-line settings, reinforcing J&J's oncology pipeline momentum. The safety profile was consistent with each drug's known profile, which could support regulatory submissions. With J&J trading near its 52-week high, this data adds a potential blockbuster indication to its hematology portfolio.
At the time of this announcement, JNJ was trading at $257.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $619.7B. The 52-week trading range was $164.23 to $269.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.